Difference between revisions of "Part:BBa K2583005"
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
 
<partinfo>BBa_K2583005 short</partinfo>
 
<partinfo>BBa_K2583005 short</partinfo>
  
−
This part is consisted of coding reigion of HRH4 and ADH1 terminator
+
This part is consisted of coding reigion of HRH4 and ADH1 terminator.
 +
 
 +
==MIT MAHE 2020==
 +
'''Summary'''
 +
 
 +
Anti-CD19 (αCD19) is a CD19 scFv. Its heavy-chain variable region (αCD19a) and the light-chain variable region (αCD19b) are fused using a glycine-rich peptide linker. B-lymphocyte antigen CD19, also known as CD19 molecule (Cluster of Differentiation 19) is a transmembrane protein that in humans is encoded by the gene CD19. CD19 plays two major roles for B cells: (1) it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane; (2) it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. Anti-CD19 can be used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19.
 +
 
 +
==References==
 +
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. (2016). The New England journal of medicine, 374(10), 998. https://doi.org/10.1056/NEJMx160005 
 +
 
 +
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017–4023. https://doi.org/10.1182/blood-2014-12-580068
 +
 
 +
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016). Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell, 167(2), 419–432.e16. https://doi.org/10.1016/j.cell.2016.09.011
 +
 
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here
 
===Usage and Biology===
 
===Usage and Biology===

Latest revision as of 18:45, 20 October 2020


HRH4-ADH1_terminator

This part is consisted of coding reigion of HRH4 and ADH1 terminator.

MIT MAHE 2020

Summary

Anti-CD19 (αCD19) is a CD19 scFv. Its heavy-chain variable region (αCD19a) and the light-chain variable region (αCD19b) are fused using a glycine-rich peptide linker. B-lymphocyte antigen CD19, also known as CD19 molecule (Cluster of Differentiation 19) is a transmembrane protein that in humans is encoded by the gene CD19. CD19 plays two major roles for B cells: (1) it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane; (2) it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. Anti-CD19 can be used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19.

References

Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. (2016). The New England journal of medicine, 374(10), 998. https://doi.org/10.1056/NEJMx160005

Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood, 125(26), 4017–4023. https://doi.org/10.1182/blood-2014-12-580068

Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016). Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell, 167(2), 419–432.e16. https://doi.org/10.1016/j.cell.2016.09.011

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 706
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI site found at 856